PTSD Trial, Recruiting (NCT06931093)

PTSD Trial, Recruiting NCT06931093 Sponsor: Peking University Condition: PTSD

Printed from Voxsanity (voxsanity.com.au) — NCT06931093 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Ptsd

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Be between 10 and 18 years old
Have symptoms that meet the criteria for Complex PTSD (C-PTSD), meaning they experience at least one symptom from each of the trauma-related symptom groups, as well as difficulties with emotions, relationships, or sense of self (confirm with trial site)
Be able to read and write well enough to complete written tasks as part of the study
Be able to understand what the study involves and complete the required assessments
Be willing to give written agreement to take part, and have a parent or legal guardian also give their written agreement

Who may not be able to join:

Have a serious mental health or brain development condition, such as schizophrenia, bipolar I disorder, autism spectrum disorder, or an intellectual disability, that could affect participation
Have a serious physical health condition that would make it hard to take part in the treatment activities
Have had thoughts of suicide at any point in the last six months
Still be experiencing or regularly exposed to traumatic events at the time of the study
Currently be receiving another type of therapy specifically focused on treating trauma

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 00861062756953

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06931093

Sponsor: Peking University

Phase: Not Applicable

Status: Recruiting

Condition: PTSD

Trial contact: 00861062756953

More information: https://clinicaltrials.gov/study/NCT06931093

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Be between 10 and 18 years old
Have symptoms that meet the criteria for Complex PTSD (C-PTSD), meaning they experience at least one symptom from each of the trauma-related symptom groups, as well as difficulties with emotions, relationships, or sense of self (confirm with trial site)
Be able to read and write well enough to complete written tasks as part of the study
Be able to understand what the study involves and complete the required assessments
Be willing to give written agreement to take part, and have a parent or legal guardian also give their written agreement

Who may not be able to join:

Have a serious mental health or brain development condition, such as schizophrenia, bipolar I disorder, autism spectrum disorder, or an intellectual disability, that could affect participation
Have a serious physical health condition that would make it hard to take part in the treatment activities
Have had thoughts of suicide at any point in the last six months
Still be experiencing or regularly exposed to traumatic events at the time of the study
Currently be receiving another type of therapy specifically focused on treating trauma

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Peking University

Registry

ClinicalTrials.gov

Start date

10 April 2025

Est. completion

10 March 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

CPTSD Symptom Severity (self-report); CPTSD Symptom Severity(interview)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov